Tatsuya Kobayashi

This paper identifies a novel HDAC inhibitor, STR-V-53, that effectively targets HCC and enhances immunotherapy responses in mouse models.

Liver fibrosis limits the survival benefit of multikinase inhibitor immunotherapy in hepatocellular carcinoma by promoting innate immune-mediated hepatotoxicity despite preserved tumor control.

This study shows that reduced glycolysis in chondrocytes expands the resting zone of the growth plate through acetyl-CoA deficiency and epigenetic activation of FGFR3 signaling.

The paper alters miR-140-5p and -3p stoichiometry in mice to identify their physiological targets and roles in bone development.

This paper generates a mouse model with activated K-ras in mesenchymal progenitors to study Noonan Syndrome-like bone defects and shows that MEK inhibition during mid-gestation rescues these defects.